Replies to post #1807 on Hepion Pharmaceuticals Inc (HEPA)

[Bertsllc]

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep. 21, 2021 4:19 PM ET Hepion Pharmaceuticals, Inc. (HEPA)

https://seekingalpha.com/article/4456410-additional-phase-iia-data-confirms-hepions-crv431-as-a-very-promising-nash-candidate-drug?mail_subject=francisco-javier-garcia-additional-phase-iia-data-confirms-hepion-s-crv431-as-a-very-promising-nash-candidate-drug&utm_campaign=rta-author-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha

Given the direct relationship that the level of the Pro-C3 biomarker has with liver fibrosis, we are going to compare the behavior of the Pro-C3 biomarker in different trials carried out by companies with candidate drugs for NASH and thus be able to determine if the data provided by Hepion is promising.